Sciencast Management LP Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Sciencast Management LP acquired a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 10,624 shares of the biopharmaceutical company’s stock, valued at approximately $100,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Amicus Therapeutics in the 3rd quarter valued at about $55,000. R Squared Ltd purchased a new position in shares of Amicus Therapeutics in the 4th quarter valued at about $79,000. Virtu Financial LLC purchased a new position in shares of Amicus Therapeutics in the 3rd quarter valued at about $107,000. KBC Group NV increased its stake in shares of Amicus Therapeutics by 44.4% in the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 3,120 shares in the last quarter. Finally, Stephens Inc. AR purchased a new position in shares of Amicus Therapeutics in the 4th quarter valued at about $101,000.

Amicus Therapeutics Price Performance

FOLD stock opened at $9.01 on Monday. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. The business has a 50 day simple moving average of $9.35 and a 200-day simple moving average of $10.06. The firm has a market capitalization of $2.77 billion, a PE ratio of -50.06, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69. Amicus Therapeutics, Inc. has a 1 year low of $8.55 and a 1 year high of $12.65.

Wall Street Analysts Forecast Growth

FOLD has been the subject of several recent analyst reports. Wells Fargo & Company cut their price target on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research note on Thursday, February 20th. StockNews.com lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, February 20th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Cantor Fitzgerald reiterated an “overweight” rating and set a $21.00 price objective on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, Amicus Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $16.75.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.